drugset / Trial / NCT05413421
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
The purpose of this study is to establish the safety and preliminary antitumor activity of ORIC-944 as a single agent and in combinations with ARPIs in patients with metastatic prostate cancer.
Timeline
- Start
- 2022-06-01
- Primary completion
- 2027-06
- Completion
- 2028-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | 1000 mg | Oral |
| Subject | Apalutamide | Small molecule | 240 mg | Oral |
| Subject | Darolutamide | Other / unclassified | 600 mg | Oral |
| Subject | Enzalutamide | Other / unclassified | 160 mg | Oral |
| Subject | ORIC-944 | Small molecule | — | Oral |